Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging.

PURPOSE: To assess diagnostic sensitivity of radial T1-weighted gradient-echo (radial volumetric interpolated breath-hold examination [VIBE]) magnetic resonance (MR) imaging, positron emission tomography (PET), and combined simultaneous PET and MR imaging with an integrated PET/MR system in the detection of lung nodules, with combined PET and computed tomography (CT) as a reference. MATERIALS AND METHODS: In this institutional review board-approved HIPAA-compliant prospective study, 32 patients with tumors who underwent clinically warranted fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT followed by PET/MR imaging were included. In all patients, the thorax station was examined with free-breathing radial VIBE MR imaging and simultaneously acquired PET data. Presence and size of nodules and FDG avidity were assessed on PET/CT, radial VIBE, PET, and PET/MR images. Percentage of nodules detected on radial VIBE and PET images was compared with that on PET/MR images by using generalized estimating equations. Maximum standardized uptake value (SUVmax) in pulmonary nodules with a diameter of at least 1 cm was compared between PET/CT and PET/MR imaging with Pearson rank correlation. RESULTS: A total of 69 nodules, including 45 FDG-avid nodules, were detected with PET/CT. The sensitivity of PET/MR imaging was 70.3% for all nodules, 95.6% for FDG-avid nodules, and 88.6% for nodules 0.5 cm in diameter or larger. PET/MR imaging had higher sensitivity than PET for all nodules (70.3% vs 61.6%, P = .002) and higher sensitivity than MR imaging for FDG-avid nodules (95.6% vs 80.0%, P = .008). There was a significantly strong correlation between SUVmax of pulmonary nodules obtained with PET/CT and that obtained with PET/MR imaging (r = 0.96, P < .001). CONCLUSION: Radial VIBE and PET data acquired simultaneously with PET/MR imaging have high sensitivity in the detection of FDG-avid nodules and nodules 0.5 cm in diameter or larger, with low sensitivity for small non-FDG-avid nodules.

Ductal Carcinoma in Situ: Current Concepts in Biology, Imaging, and Treatment.

Ductal carcinoma in situ (DCIS) of the breast is a group of heterogeneous epithelial proliferations confined to the milk ducts that nearly always present in asymptomatic women on breast cancer screening. A stage 0, preinvasive breast cancer, increased detection of DCIS was initially hailed as a means to prevent invasive breast cancer through surgical treatment with adjuvant radiation and/or endocrine therapies. However, controversy in the medical community has emerged in the past two decades that a fraction of DCIS represents overdiagnosis, leading to unnecessary treatments and resulting morbidity. The imaging hallmarks of DCIS include linearly or segmentally distributed calcifications on mammography or nonmass enhancement on breast MRI. Imaging features have been shown to reflect the biological heterogeneity of DCIS lesions, with recent studies indicating MRI may identify a greater fraction of higher-grade lesions than mammography does. There is strong interest in the surgical, imaging, and oncology communities to better align DCIS management with biology, which has resulted in trials of active surveillance and therapy that is less aggressive. However, risk stratification of DCIS remains imperfect, which has limited the development of precision therapy approaches matched to DCIS aggressiveness. Accordingly, there are opportunities for breast imaging radiologists to assist the oncology community by leveraging advanced imaging techniques to identify appropriate patients for the less aggressive DCIS treatments.